Author

JeanPierre Coaquira Castro

Observed names: J Coaquira Castro, J. Coaquira Castro

Institution: BeOne Medicines (Switzerland)

Observed institution: BeOne Medicines (Switzerland)

ORCID: 0009-0001-7063-2420

Observed ORCID: 0009-0001-7063-2420

OpenAlex ID: A5111328189

Comparative effectiveness and safety of tislelizumab versus other anti–PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non–small cell lung cancer: Systematic literature review and network meta-analysis

2025 · Nicolas Girard, Ji-Youn Han, et al. · Lung Cancer · 6

Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons

2025 · Jaffer A. Ajani, Kaijun Wang, et al. · Advances in Therapy

CO9 Systematic Literature Review (SLR) of Disease Burden Related to First-Line (1L) Unresectable, Locally Advanced, or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

2024 · E Smyth, A Sibiga, et al. · Value in Health

SA31 Systematic Literature Review (SLR) of Randomized Controlled Trials (RCTs) of Treatments for First-Line (1L) Gastric Cancer/Gastroesophageal Junction Adenocarcinoma (GC/GEJ) in Adult Patients

2024 · E. Smyth, T. Kangappaden, et al. · Value in Health

1417P Comparative efficacy and safety of tislelizumab versus anti-PD-1 treatments in second-line esophageal squamous cell carcinoma: Simulated treatment comparisons

2024 · E.C. Smyth, J.A. Ajani, et al. · Annals of Oncology

EE669 Quality of Life and Economic Burden of Advanced Non-Small Cell Lung Cancer in Medium and Small Markets (MED&SM): A Systematic Literature Review

2023 · M.J. Ahn, D.T.S. Weng, et al. · Value in Health

Works count: 6

Citation count: 6

H-index: 1

I10-index: